The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma - refine.bio

GSE98905

Homo sapiens

10 Downloadable Samples

Technology Badge Icon

Affymetrix Human Genome U219 Array (hgu219)

Submitter Supplied Information

Description

Double Hit Lymphoma (DHL) were treated with the BRD4 inhibitor 100 nM CPI203 for 6h

PubMed ID

Publication Title

The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma.

Total Samples

10

Submitter’s Institution

Authors

Esteve-Arenys A, Valero JG, Chamorro-Jorganes A, Gonzalez D, Rodriguez V, Dlouhy I, Salaverria I, Campo E, Colomer D, Martinez A, Rymkiewicz G, Pérez-Galán P, Lopez-Guillermo A, Roué G

Source Repository

Gene Expression Omnibus (GEO)

No rows found

Loading...